Creating new chiral small molecules for drug development
Official title: Enantioenriched Nitrogen-Containing Small Molecules via Stereoselective Carbon-Carbon Bond Construction
Funded at University of North Carolina Wilmington · NIH-10973829 · Data updated 2026-11-12
This study is exploring new ways to create special tiny molecules that can help make better medicines, which could lead to new drugs that work more effectively and safely for patients.
Quick facts
| Grant type | R15 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of North Carolina Wilmington NIH-funded |
| Lab location | 1 site (Wilmington, United States) |
| Project start | September 10, 2024 |
| Project end | August 31, 2027 |
| Funding year | 2024 |
| Award (this year) | $369,199 |
| NIH project number | 1R15GM155801-01 |
| Project ID | NIH-10973829 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for participation or benefit from this research would be individuals with conditions that could be treated by new nitrogen-containing pharmaceuticals.
✕Less likely to help
Patients who are not seeking new medication options or those with conditions that do not respond to nitrogen-containing drugs may not benefit from this research.
What this research studies
This research focuses on developing new methods to synthesize chiral nitrogen-containing small molecules, which are crucial for creating effective pharmaceuticals. The approach involves using advanced chemical techniques, such as ring opening of aziridines and epoxides, to produce these molecules in a stereoselective manner. By employing chiral Lewis acid catalysis, the researchers aim to enhance the efficiency of carbon-carbon bond formation, ultimately leading to the discovery of novel drugs. Patients may benefit from this research as it could lead to the development of new medications with improved efficacy and safety profiles.
Why it matters
Potential benefit: If successful, this research could lead to the creation of more effective and safer medications for various health conditions.
How similar studies have gone: Other research has shown success in developing chiral small molecules using similar stereoselective methods, indicating a promising avenue for drug development.
Where this research is happening
-
University of North Carolina Wilmington
Wilmington, United States Active
Researchers
- Principal investigator: Morgan, Jeremy B — University of North Carolina Wilmington
- Study coordinator: Morgan, Jeremy B
Related research
Other NIH-funded projects on the same topics.
-
How teen binge drinking changes developing brain cells in the hippocampus
This work looks at how repeated binge drinking during adolescence can change the way developing brain cells in the hippocampus grow and connect, which may affect learning and memory later in life.
-
Non-canonical roles of energy-boosting enzymes in stress resilience
Aiming to understand how certain energy-boosting enzymes help cells cope with stress, using a worm model to uncover tissues where this protection works best and how it could help aging and disease.
-
How certain peptides interact with cell membranes
This study is looking at how tiny protein pieces called β-hairpin peptides interact with cell membranes, which could help us design better treatments and improve how medicines are delivered to patients.
-
Understanding how learning affects substance use disorders
This study looks at how learning and memory affect addiction and relapse by observing how rats connect different smells with rewards, which could help us understand similar behaviors in people dealing with substance use disorders.
-
How digestion affects the benefits of Ashwagandha
This study is looking at how your body breaks down Ashwagandha, a popular herbal supplement, to see which helpful parts can actually get into your bloodstream and how that might help with anxiety and depression.
-
Targeting prostate cancer cells with DNA-damaging toxins
This study is working on new treatments for prostate cancer that aim to directly attack cancer cells and make them die, while also trying to reduce the side effects of chemotherapy.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.